Coherus Oncology Business Summary

Coherus Oncology, Inc. (CHRS) is a commercial-stage biopharmaceutical company that generates revenue primarily through the sale of proprietary immuno-oncology therapeutics and strategic licensing agreements. Following its 2025 divestiture of the UDENYCA biosimilar franchise, the company transitioned into a pure-play oncology entity focused on its core segment: innovative cancer treatments. Revenue is currently anchored by LOQTORZI (toripalimab-tpzi), the first FDA-approved PD-1 inhibitor for nasopharyngeal carcinoma, supplemented by a pipeline of next-generation assets including casdozokitug (anti-IL-27) and CHS-114 (anti-CCR8). Coherus competes directly with oncology-focused firms such as Iovance Biotherapeutics, Vir Biotechnology, and Nanobiotix, positioning itself as a specialist in niche solid tumor indications and novel combination therapies that enhance immune response in the tumor microenvironment. The company was founded in 2010 by a veteran team including Chairman and CEO Dennis M. Lanfear, S. Stephen Glover, and George Montgomery. Lanfear, a former Amgen executive, leads a management team that includes Chief Financial Officer Bryan J. McMichael, Chief Technical Officer Rich Hameister, and Chief Scientific and Development Officer Theresa LaVallee, Ph.D., who oversees the clinical advancement of the toripalimab combinations. Coherus is backed by notable institutional investors, including KKR, whose partner Ali J. Satvat serves on the Board of Directors alongside industry veterans like Rita Karachun and Michael Ryan, formerly of Bristol Myers Squibb. This leadership group leverages deep expertise in biologics manufacturing and commercialization to navigate the company’s strategic pivot toward high-value, innovative oncology assets.